LGNDLigand Pharmaceuticals Incorporated

$4B

FY 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$120M-52.2% YoY

Gross Profit

$109M90.6% margin

Operating Income

$807M671.0% margin

Net Income

$629M523.2% margin

EPS (Diluted)

$31.85

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$32M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$728M

Stockholders' Equity

$767M

Cash & Equivalents

$72M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$120M	$251M	-52.2%
Gross Profit	$109M	$245M	-55.6%
Operating Income	$807M	$164M	+392.9%
Net Income	$629M	$143M	+339.1%

LGND FY 2019 Earnings — Ligand Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena